UnknownPhase 4

Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.

China60 participantsStarted 2022-01-01

Plain-language summary

To study the effects of pioglitazone combined with metformin and metformin on gonadal and metabolic profiles in PCOS patients with BMI \< 24 in China. 60 cases of nonobese PCOS patients were collected from Shengjing hospital. The intervention period was 3 months after intervention with met or met + ph. To evaluate the improvement of met or met + ph in the treatment of hyperandremia, glucose metabolism, BMI, waist circumference, menstruation, hairiness and acne in PCOS patients.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Females 18 years to 40 years of age Diagnosed as PCOS by the 2003 Rotterdam criteria
✓. BMI\<24 kg/m2
✓. No pregnant plan in recent 6 months
✓. Written consent for participation in the study

Exclusion criteria

✕. type 1 or type 2 diabetes mellitus
✕. Subjects have other endocrine diseases, such as adrenal hyperplasias or tumor, androgen-secreting tumors, Cushing's syndrome, thyroid diseases, and hyperprolactinemia
✕. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
✕. Serious systemic disease or malignant tumor
✕. History of pancreatitis (chronic, acute or recurrent)
✕. Body weight change ≥10% at 3 months before treatment
✕. Used oral contraceptives or sex hormone drugs in the past 1 month
✕. Used oral glucocorticoids in the past 1 month

What they're measuring

Changes in sex hormone binding globulin (SHBG)

Timeframe: 12 weeks

Trial details

NCT IDNCT05519813

SponsorBing He

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Polycystic Ovary Syndrome trials